We Know IBD - Healthcare Providers
See If You Are Eligible
Call (844) 609-0363

For

HEALTHCARE
PROVIDERS

HOW YOU
CAN HELP

You may have patients with IBD who are still seeking effective treatment options due to inadequate response to their current medications, which can be frustrating.

Because there is still a need to find treatments that work for everyone, let your patients know that another option is participating in clinical research. The following IBD clinical trials are available:

ULCERATIVE COLITIS

The ANTHEM-UC Study is evaluating the efficacy and safety of an oral investigational medication for the treatment of moderately to severely active ulcerative colitis (UC).

  • Are at least 18 years old
  • Have a documented diagnosis of UC at least 12 weeks prior to screening, with colitis confirmed at any time in the past by radiography, histology, and/or endoscopy; a biopsy report supporting the diagnosis must be available in the source documentation
  • Have moderately to severely active UC, defined as baseline (Week 0) modified Mayo score of 5 to 9 (inclusive)

For additional information: Download the ANTHEM-UC HCP Study Guide.

The DUET-UC Study is evaluating the safety and efficacy of a combination of two investigational medications compared to each monotherapy and placebo in adults with moderately to severely active ulcerative colitis.

  • Are 18 to 65 years old
  • Have been diagnosed with UC at least 3 months prior to screening (a biopsy report supporting the diagnosis is required)
  • Are experiencing moderately to severely active UC, defined as a baseline (Week 0) modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopy subscore obtained during the central review of the screening endoscopy (screening endoscopy subscore >2 required for inclusion)
  • Have demonstrated a lack of initial response, loss of response to, or intolerance to advanced therapy (TNFα antagonist, an IL-12/23 antagonist, a4b7 integrin antagonist, approved JAK inhibitor, or S1P receptor modulator therapies)

For additional information: Download the DUET-UC HCP Study Guide.

CROHN'S DISEASE

duet-uc

The DUET-CD Study is evaluating the safety and efficacy of a combination of two investigational medications compared to each monotherapy and placebo in adults with moderately to severely active Crohn's disease.

  • Are 18 to 65 years old
  • Have been diagnosed with Crohn's disease or fistulizing Crohn's disease with colitis, ileitis, or ileocolitis at least 3 months prior to screening
  • Are experiencing clinically active Crohn's disease defined as a baseline CDAI score greater than or equal to 220 but less than or equal to 450 and either a mean daily SF count greater than or equal to 4 based on the unweighted CDAI component of the number of liquid or very soft stools OR a mean daily AP score greater than or equal to 2 based on the unweighted CDAI component of AP
  • Have endoscopic evidence of active ileal and/or colonic Crohn's disease as assessed by central endoscopy reading at the screening endoscopy, defined as a screening SES-CD greater than or equal to 6 (for patients with colonic or ileocolonic disease) or greater than or equal to 4 (for patients with isolated ileal disease)
  • Have demonstrated a lack of initial response, loss of response to, or intolerance to advanced therapy (TNFα antagonist, an IL-12/23 antagonist, or a4b7 integrin antagonist therapies)

For additional information: Download the DUET-CD HCP Study Guide.

There are trial clinics located throughout the United States.
FIND A LOCATION NEAR YOU
To see a list of participating trial clinics around the world, visit this page.
VIEW PARTICIPATING COUNTRIES

If you have patients that may be a candidate for one of these clinical trials, or if you would like to share this information with a colleague, here's what you can do:

Share this website to provide education and awareness about these clinical trials. Patients can also take a simple questionnaire to see if they may be eligible.

Share This

Our team is happy to answer questions from you or your patients. Call us at the number below to be connected with a nurse who can help direct you to a principal investigator for more details. You can also encourage your patients to contact the nurses at the number below to ask any questions they may have and see if they may be eligible to participate in one of the trials.

Call (844) 609-0363
chevron

Download and share a patient fact sheet with more information on the trial.

    CROHN'S DISEASE

  • Download the DUET-CD Patient Fact Sheet.

    ULCERATIVE COLITIS

  • Download the ANTHEM-UC Patient Fact Sheet.
  • Download the DUET-UC Patient Fact Sheet.
chevron

ABOUT JANSSEN

At Janssen, we're researching ways to one day make disease a thing of the past.

We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to help make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. Janssen's commitment to IBD drug development spans over two decades, and our portfolio of IBD clinical trials aims to bring potential investigational medications to patients as quickly as possible through research.

Visit Global Trial Finder to locate Janssen clinical trials that may be looking for participants all around the world.